Part 2 – Case Discussion
Daniel A. Pollyea, MD, MS, presents the case of patient “A.B.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Gabriel N. Mannis, MD. The virtual roundtable panel discusses unique features of the case and explores hypothetical variations of the circumstances, as well as offering insights into how the latest data from clinical trials may impact the future of treatment for patients with acute myeloid leukemia (AML).
Click here to learn more by viewing Part 3 – Case Discussion & Wrap-up.
Disclosures: Brian A. Jonas, MD, PhD, FACP Consulting Fees: AbbVie, Genentech, GlycoMimetics, Jazz, Takeda Contracted Research: 47, AbbVie, Amgen, AROG, Celgene, Daiichi-Sankyo, Forma, Genentech/Roche, GMI, Hanmi, Jazz, Pfizer, PCYC Travel Reimbursement: AbbVie Gabriel N. Mannis, MD Consulting Fees: AbbVie, Agios, BMS/Celgene, Genentech, Pfizer Contracted Research: Gilead/Forty Seven, Glycomimetics, Jazz Daniel A. Pollyea, MD, MS Consulting Fees: Celgene, Abbvie, Genentech, Novartis, Karyopharm, Syndax, BMS Other: Takeda, Syros, Kiadis, Foghorn, Aprea, Gilead, Amgen, Astellas References:
- Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014 Aug;15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6. PMID: 25008258; PMCID: PMC4137593.
- Stone RM, Larson RA, Döhner H. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017 Nov 9;377(19):1903. doi: 10.1056/NEJMc1711340. PMID: 29117486.
